Home › Therapeutic areas › Other gastrointestinal agents
Japan market screening · Therapeutic class
その他の消化器官用薬 · Japan Standard Commodity Classification
30 molecules in this class are marketed in Japan across 202 products. 47 of those products are not shipping normally today — 23.3% of the class. Supply status is reported to the Ministry of Health, Labour and Welfare and updated daily.
Ordered by how many products compete. Constrained means limited supply or supply suspended; supply suspended does not mean discontinued.
| Molecule | Products | Companies | Constrained | Supply mix |
|---|---|---|---|---|
| Mosapride Citrate Hydrateモサプリドクエン酸塩水和物 | 44 | 22 | 1 | |
| Domperidoneドンペリドン | 33 | 11 | 9 | |
| Granisetron Hydrochlorideグラニセトロン塩酸塩 | 30 | 10 | 7 | |
| Mesalazineメサラジン | 16 | 8 | 11 | |
| Metoclopramideメトクロプラミド | 11 | 5 | 6 | |
| Triamcinolone Acetonideトリアムシノロンアセトニド | 9 | 6 | 3 | |
| Palonosetron Hydrochlorideパロノセトロン塩酸塩 | 7 | 5 | — | |
| Aprepitantアプレピタント | 6 | 2 | — | |
| Ramosetron Hydrochlorideラモセトロン塩酸塩 | 6 | 2 | — | |
| Mirikizumab (Genetical Recombination)ミリキズマブ（遺伝子組換え） | 5 | 1 | — | |
| Ondansetron Hydrochloride Hydrateオンダンセトロン塩酸塩水和物 | 4 | 3 | 1 | |
| Trimebutine Maleateトリメブチンマレイン酸塩 | 4 | 3 | 2 | |
| Polycarbophil Calciumポリカルボフィルカルシウム | 3 | 2 | 2 | |
| Vedolizumab (Genetical Recombination)ベドリズマブ（遺伝子組換え） | 3 | 1 | — | |
| Cevimeline Hydrochloride Hydrateセビメリン塩酸塩水和物 | 2 | 2 | — | |
| Domiphen Bromideドミフェン臭化物 | 2 | 1 | — | |
| Infliximab (Genetical Recombination) [Infliximab Biosimilar 2]インフリキシマブ（遺伝子組換え）［インフリキシマブ後続２］ | 2 | 2 | 2 | |
| Itopride Hydrochlorideイトプリド塩酸塩 | 2 | 2 | 1 | |
| Ozanimod Hydrochlorideオザニモド塩酸塩 | 2 | 1 | — | |
| Acotiamide Hydrochloride Hydrateアコチアミド塩酸塩水和物 | 1 | 1 | — | |
| Carotegrast Methylカロテグラストメチル | 1 | 1 | — | |
| Cetylpyridinium Chloride Hydrateセチルピリジニウム塩化物水和物 | 1 | 1 | 1 | |
| Dequalinium Chlorideデカリニウム塩化物 | 1 | 1 | 1 | |
| Etrasimod L-ArginineエトラシモドＬ－アルギニン | 1 | 1 | — | |
| Fosaprepitant Meglumineホスアプレピタントメグルミン | 1 | 1 | — | |
| Fosnetupitant Chloride Hydrochlorideホスネツピタント塩化物塩酸塩 | 1 | 1 | — | |
| Infliximab (Genetical Recombination)インフリキシマブ（遺伝子組換え） | 1 | 1 | — | |
| Infliximab (Genetical Recombination) [Infliximab Biosimilar 1]インフリキシマブ（遺伝子組換え）［インフリキシマブ後続１］ | 1 | 1 | — | |
| Infliximab (Genetical Recombination) [Infliximab Biosimilar 3]インフリキシマブ（遺伝子組換え）［インフリキシマブ後続３］ | 1 | 1 | — | |
| Linaclotideリナクロチド | 1 | 1 | — |
Products counts every marketed product across all strengths and forms, not companies. Companies is the number of companies marketing that molecule; the same company may appear under several molecules, so the column does not add up to a class total. Market size sits on each molecule's own page, valued at national price rather than transaction price. Figures are as at 2026-08-28.
Tell us which molecules matter to you. We will tell you what the public data can and cannot answer before you commission anything.
Send an enquiryOur Database Division replies in English within three business days (Japan time).